AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRO MEDICUS LTD

210.780

+2.1001.01%

Volume:278.52K

Turnover:58.75M

Market Cap:22.02B

PE:224.38

High:213.840

Open:209.000

Low:208.360

Close:208.680

Loading ...

Overview Company News Filings

Pro Medicus Ltd - Contract Will See Co's Visage 7 Enterprise Imaging Platform Implemented Throughout Lucidhealth

THOMSON REUTERS

Pro Medicus Ltd - Pme Signs a$40M, 7-Year Contract With Lucidhealth

THOMSON REUTERS

Steve Johnson: Two small caps on a run and the uncovered gems that could be next

3 of the best ASX tech shares to buy in March

24 ASX 200 shares with ex-dividend dates next week

3 High Growth Tech Stocks in Australia

Simply Wall St.

3 reasons I'd still buy the iShares S&P 500 ETF (IVV) after big gains

Mineral Resources still a sell on debt burden, iron ore and lithium prices - Datt Capital

Should you buy the dip on ASX healthcare stocks CSL, Cochlear and Pro Medicus?

Australian companies that thrive in economic downturns

Top brokers name 3 ASX shares to buy next week

Pro Medicus Limited (ASX:PME) Released Earnings Last Week And Analysts Lifted Their Price Target To AU$253

Simply Wall St.

Brokers name 3 ASX shares to buy today

Leading broker upgrades Pro Medicus shares to buy rating

Here's Why We Think Pro Medicus (ASX:PME) Might Deserve Your Attention Today

Simply Wall St.

Pro Medicus hypes up ‘unprecedented success’ in US push – but market not so sold

The Market Herald

ASX Market Update: Index touches new record as Chemist Warehouse debuts | Feb 13, 2025

The Market Herald

"I’ll be buying" – Why Jun Bei Liu sees more upside in Pro Medicus

Pro Medicus logs 42.7% increase in net profit as major contracts drive growth

Pro Medicus share price storms higher on record-breaking results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PME.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PME.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PME.AU\",,,,,undefined,":{"symbol":"PME.AU","market":"AU","secType":"STK","nameCN":"PRO MEDICUS LTD","latestPrice":210.78,"timestamp":1745475120000,"preClose":208.68,"halted":0,"volume":278519,"delay":0,"nameEN":"PRO MEDICUS LTD","floatShares":52960584,"shares":104462909,"eps":0.939404,"marketStatus":"Closed","change":2.1,"latestTime":"04-24 16:12:00 AEST","open":209,"high":213.84,"low":208.36,"amount":58751585,"amplitude":0.02626,"askPrice":211.32,"askSize":25,"bidPrice":210.73,"bidSize":198,"shortable":3,"etf":0,"ttmEps":0.939404,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745798400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":208.68,"dividendRate":0.00223,"openAndCloseTimeList":[[1745452800000,1745474400000]],"volumeRatio":1.444581,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PME.AU\",,,,,undefined,":{"symbol":"PME.AU","floatShares":52960584,"roa":"32.90%","roe":"51.53%","lyrEps":0.792737,"volumeRatio":1.444581,"shares":104462909,"dividePrice":0.47,"high":213.84,"amplitude":0.02626,"preClose":208.68,"low":208.36,"week52Low":106.728,"pbRate":"99.07","psRate":"119.29","week52High":298.706,"institutionHeld":0,"latestPrice":210.78,"committee":0.775785,"eps":0.939404,"divideRate":0.00223,"volume":278519,"delay":0,"ttmEps":0.939404,"open":209,"prevYearClose":249.891,"prevWeekClose":207.17,"prevMonthClose":199.79,"prevQuarterClose":199.79,"fiveDayClose":209.52,"twentyDayClose":229.89,"sixtyDayClose":268.644},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PME.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516822540","title":"Pro Medicus Ltd - Contract Will See Co's Visage 7 Enterprise Imaging Platform Implemented Throughout Lucidhealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2516822540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516822540?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:21","pubTimestamp":1740954108,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nFWN3PL005:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2516408215","title":"Pro Medicus Ltd - Pme Signs a$40M, 7-Year Contract With Lucidhealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2516408215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516408215?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:21","pubTimestamp":1740954108,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nFWN3PL005:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PME.AU","BK7094"],"gpt_icon":0},{"id":"2514311685","title":"Steve Johnson: Two small caps on a run and the uncovered gems that could be next","url":"https://stock-news.laohu8.com/highlight/detail?id=2514311685","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514311685?lang=en_us&edition=fundamental","pubTime":"2025-02-28 14:57","pubTimestamp":1740725877,"startTime":"0","endTime":"0","summary":"The appeal of investing in small caps is clear. The potential to find that overlooked gem that can burst onto the scene is real, and it is a corner of the market where active managers can exploit inefficiencies.The opportunity exists for several reasons - stocks are often illiquid, creating a barrier for larger investors; there is less analyst coverage and not all investors are playing the same game - time horizons can vary greatly depending on the strategy of the investor.But it's not all plain sailing, and value can be destroyed as quickly as it can be made. Most small-cap investors will readily chew your ear off with a long list of war wounds that come with the territory.Unsurprisingly, most of the pain has been in stocks where valuations were rich and expectations high. The positive surprises have come from stocks that have been beaten down in recent years, such as Nanosonics  and Peoplein , where expectations were low and the re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/steve-johnson-two-small-caps-on-a-run-and-the-uncovered-gems-that-could-be-next","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/steve-johnson-two-small-caps-on-a-run-and-the-uncovered-gems-that-could-be-next","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["CAT.AU","BK7062","CCL.AU","BRG.AU","BK7158","PME.AU","BVS.AU","BK7094","BK7084","BK7057","BK7126","NWL.AU","BK7500","PNI.AU","NAN.AU","BK7503","BK7119","BK7033","BK7016","TYR.AU","PPE.AU"],"gpt_icon":0},{"id":"2514332469","title":"3 of the best ASX tech shares to buy in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2514332469","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514332469?lang=en_us&edition=fundamental","pubTime":"2025-02-28 03:24","pubTimestamp":1740684240,"startTime":"0","endTime":"0","summary":"Investors looking for top ASX tech shares to buy in March may want to consider the three companies below. These shares have been backed by analysts due to their strong market positions, growth prospec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/28/3-of-the-best-asx-tech-shares-to-buy-in-march/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7094","LU1868836757.USD","XRO.AU","LU1868836591.USD","LU2471134796.USD","BK4588","LU2237443465.HKD","LU1868837136.USD","360.AU","LU2237443978.SGD","IE00BSNM7G36.USD","LU2471134523.USD","LIF","IE00B19Z3B42.SGD","LU2237443549.SGD","MAU.AU","IE00B19Z3581.USD","BK4504","BK7503","IE00BFXG1179.USD","BK7104","BK4533","LU2237438978.USD","BK7095","TAM.AU","LU1791807156.HKD","BK4585","LU2750360997.AUD","BK4127","PME.AU","IE0034235188.USD","IE0002270589.USD","LU2471134952.CNY","BK7016","BK4023","BK4516","LU2237443895.HKD","LU0106831901.USD","LU2237443382.USD","LU2471134879.HKD","BK4550","LU0096364046.USD","LU1868836914.USD","LU1868837300.USD","LU2237443622.USD","LU0061475181.USD","BK4552","LU2750360641.GBP","IE0004086264.USD","IE0004091025.USD"],"gpt_icon":0},{"id":"2513976253","title":"24 ASX 200 shares with ex-dividend dates next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976253","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513976253?lang=en_us&edition=fundamental","pubTime":"2025-02-21 12:58","pubTimestamp":1740113880,"startTime":"0","endTime":"0","summary":"With most of these dividend announcements, the payday usually comes soon after.But before a dividend payday, there must be an ex-dividend date. That's when the line is officially drawn in the sand, indicating which investors are eligible to receive said dividend and which are not.The rule is that any investor with shares to their name as of the market close before a company's ex-dividend date gets the paycheque. Anyone who buys on or after the ex-dividend date misses out, with the seller retaining the rights to the dividend.Next week will see a huge chunk of the ASX 200 trade ex-dividend for their latest payouts.With that in mind, here are the 24 ASX 200 dividend shares that will go through this process next week.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/21/24-asx-200-shares-with-ex-dividend-dates-next-week/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7083","BK7053","WHC.AU","HMC.AU","BK7162","BEN.AU","BK7511","BK7094","BK7050","DOW.AU","BK7063","BK7505","BK7041","ORA.AU","IPH.AU","CTD.AU","BGA.AU","FMG.AU","BK7136","BK7153","VCX.AU","AMP.AU","BK7142","CGF.AU","AMC.AU","BK7005","TLC.AU","BK7062","BPT.AU","BK7129","BK7139","BK7078","MFG.AU","TAH.AU","VNT.AU","BK7141","BK7070","BK7064","WES.AU","DRR.AU","BK7042","BK7507","BK7112","PME.AU","STO.AU","BK7055","AGL.AU","TLS.AU","BK7510"],"gpt_icon":1},{"id":"2512446294","title":"3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2512446294","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512446294?lang=en_us&edition=fundamental","pubTime":"2025-02-20 12:01","pubTimestamp":1740024115,"startTime":"0","endTime":"0","summary":"As the Australian market grapples with a 0.49% decline in ASX 200 futures and mixed signals from global economic events, investors are keenly watching for opportunities in high-growth sectors like technology, especially as U.S. indices like the S&P 500 reach new highs. In this context, identifying promising tech stocks involves assessing their resilience to broader market fluctuations and their ability to capitalize on emerging trends within the industry.Click here to see the full list of 51 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: Data#3 Limited provides IT solutions and services across Australia, Fiji, and the Pacific Islands with a market capitalization of A$1.24 billion.Operations: Data#3 Limited focuses on delivering a range of IT solutions and services across multiple regions, including Australia, Fiji, and the Pacific Islands. The company operates with a market capitalization of approximately A$1.24 billion.Operations: The company generates revenue p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-high-growth-tech-stocks-040155660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XJO.AU","XKO.AU","XAO.AU","BK7061","BK7094","BK7002","PME.AU","DTL.AU","SEK.AU"],"gpt_icon":0},{"id":"2512596014","title":"3 reasons I'd still buy the iShares S&P 500 ETF (IVV) after big gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2512596014","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512596014?lang=en_us&edition=fundamental","pubTime":"2025-02-20 07:24","pubTimestamp":1740007483,"startTime":"0","endTime":"0","summary":"The iShares S&P 500 ETF (ASX: IVV) has been a very strong performer in the past 12 months and the last few years. Just look at the chart below; in just one year, theexchange-traded fund (ETF)has risen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/20/3-reasons-id-still-buy-the-ishares-sp-500-etf-ivv-after-big-gains/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1244550577.SGD","SDS","USJW.SI","ROE","IE00B775H168.HKD","SG9999015945.SGD","LU0096362180.USD","LU0256863811.USD","LU0471298694.HKD","FDN","LU0786609619.USD","IE00B5949003.HKD","LU1642822529.SGD","ETF.AU","LU2111349929.HKD","IVV.AU","SH","VAS.AU","LU0820561818.USD","A200.AU","SG9999014567.USD","SSO","IVV","SPY","COST","LU0158827948.USD","LU1551013342.USD","VTS.AU","LU0943347566.SGD",".SPX","LU1623119135.USD","BK4155","LU1181866309.USD","SG9999014914.USD","LU1037948541.HKD","UPRO","LU0545039389.USD","PME.AU","OEX","OEF","WTC.AU","SPXU","BRK.A","LU0742534661.SGD","ESmain","VOO"],"gpt_icon":1},{"id":"2512491721","title":"Mineral Resources still a sell on debt burden, iron ore and lithium prices - Datt Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512491721","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512491721?lang=en_us&edition=fundamental","pubTime":"2025-02-19 11:15","pubTimestamp":1739934904,"startTime":"0","endTime":"0","summary":"Not that long ago, Mineral Resources  appeared to have everything an ASX resources investor could want. Pilbara iron ore production. Tick. Energy transition exposure via lithium production. Tick. A mining services arm that boasts the who’s who of WA mining royalty as its customers. Tick.In short: A company that produces minerals and earns money from helping others produce them – an ASX resources investor’s dream!But, for many investors, that dream is rapidly turning into a nightmare as MinRes’ share price has plummeted from around $80 in May last year, to as low as $26 this morning after the release of its H1 FY25 results.That share price journey has been punctuated by a plunge in lithium prices, subdued iron ore prices, alleged c-suite indiscretions, a burgeoning debt burden, and even bad weather.So, whilst many amateur ASX investors might be considering buying the dip on MinRes, Datt is sticking with his “Sell” call. I spoke with him about his thoughts on today’s results, as well as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/mineral-resources-still-a-sell-on-debt-burden-iron-ore-and-lithium-prices-datt-capital","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/mineral-resources-still-a-sell-on-debt-burden-iron-ore-and-lithium-prices-datt-capital","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7099","PME.AU","GMG.AU","BK7504","MIN.AU","BK7507","BK7094","BK7510","BK7155","PLS.AU","BK7095"],"gpt_icon":0},{"id":"2512979589","title":"Should you buy the dip on ASX healthcare stocks CSL, Cochlear and Pro Medicus?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512979589","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512979589?lang=en_us&edition=fundamental","pubTime":"2025-02-18 05:00","pubTimestamp":1739826009,"startTime":"0","endTime":"0","summary":"In this article, we’ll investigate the best and worst bits of the recent first-half financial year 2025 results  releases of three of the ASX’s premier healthcare companies, CSL Limited , Cochlear , and Pro Medicus .We’ll also check out the market’s response to the results, including the dip in each of their share prices, as well as all the changes in major brokers’ ratings and target prices. Do the experts think you should buy the dip on these blue-chip ASX healthcare stocks?CSL is a true Australian success story, having grown from humble beginnings as Commonwealth Serum Laboratories founded in 1916, to a globally significant healthcare company. It operates across the world with divisions including CSL Behring , CSL Seqirus , and CSL Vifor .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/should-you-buy-the-dip-on-asx-healthcare-stocks-csl-cochlear-and-pro-medicus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/should-you-buy-the-dip-on-asx-healthcare-stocks-csl-cochlear-and-pro-medicus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["IE0004086264.USD","LU0106261612.USD","CSL.AU","IE00B19Z3581.USD","BK4516","SGXZ23171101.USD","BK4086","LU1169589451.USD","LU1868837136.USD","LU1868836914.USD","BK7067","IE00B19Z3B42.SGD","LU2237443465.HKD","LU2471134796.USD","PME.AU","XJO.AU","BK4550","LU2471134952.CNY","XAO.AU","BK7501","LU1668664300.SGD","LU2237443549.SGD","HAE","LU0728928796.USD","LU1868836757.USD","LU2750360641.GBP","BK4585","BK7508","LU0061475181.USD","BK4127","LU2237438978.USD","XKO.AU","CSL","LU0205194284.USD","LU1791807156.HKD","COH.AU","LU2237443978.SGD","LU2471134879.HKD","BK7094","SG9999004303.SGD","LU0205193047.USD","LU2237443382.USD","LU0012050646.USD","BK4504","IE00B64QTZ34.USD","BK4552","LU0106831901.USD","LU1868836591.USD","LU1868837300.USD","LU2471134523.USD"],"gpt_icon":0},{"id":"2512190099","title":"Australian companies that thrive in economic downturns","url":"https://stock-news.laohu8.com/highlight/detail?id=2512190099","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512190099?lang=en_us&edition=fundamental","pubTime":"2025-02-17 11:19","pubTimestamp":1739762397,"startTime":"0","endTime":"0","summary":"It's fairly simple for Australian companies to make good profits during boom economic times, but what about when there are economic downturns?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/17/australian-companies-that-thrive-in-economic-downturns/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XKO.AU","PME.AU","XAO.AU","BK7094","TNE.AU","BK7503","EBIT","XJO.AU","BK7016"],"gpt_icon":0},{"id":"2511028036","title":"Top brokers name 3 ASX shares to buy next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2511028036","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511028036?lang=en_us&edition=fundamental","pubTime":"2025-02-16 04:15","pubTimestamp":1739650500,"startTime":"0","endTime":"0","summary":"It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Her","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/16/top-brokers-name-3-asx-shares-to-buy-next-week-16-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237443465.HKD","LU1989772840.SGD","LU1732800096.USD","CSL.AU","LU2089284900.SGD","IE0034235188.USD","LU2357305700.SGD","LU2347655156.SGD","LU2750360997.AUD","LU2271345857.HKD","PME.AU","LU2111349929.HKD","BK4581","IE0002270589.USD","BK4588","DMP.AU","LU2023251221.USD","LU2028103732.USD","BK4550","BK4552","LU0971096721.USD","LU0795875169.SGD","BK4516","LU1868836591.USD","BK4585","BK7137","LU1868837136.USD","LU1868836914.USD","LU0225283273.USD","LU0096364046.USD","LU1162221912.USD","LU0795875086.SGD","LU2237443978.SGD","IE0004086264.USD","LU0098860793.USD","LU0158827781.USD","IE0004091025.USD","LU1868836757.USD","LU2237443549.SGD","IE00BZ1G4Q59.USD","LU0320765646.SGD","BK7501","LU2471134796.USD","BK7511","IE00BKVL7J92.USD","LU0912757837.SGD","LU1668664300.SGD","BK7067","LU1720051108.HKD","LU0061475181.USD"],"gpt_icon":1},{"id":"2511633519","title":"Pro Medicus Limited (ASX:PME) Released Earnings Last Week And Analysts Lifted Their Price Target To AU$253","url":"https://stock-news.laohu8.com/highlight/detail?id=2511633519","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511633519?lang=en_us&edition=fundamental","pubTime":"2025-02-14 12:37","pubTimestamp":1739507822,"startTime":"0","endTime":"0","summary":"Last week, you might have seen that Pro Medicus Limited  released its half-yearly result to the market. The early response was not positive, with shares down 3.1% to AU$279 in the past week. Results overall were respectable, with statutory earnings of AU$0.49 per share roughly in line with what the analysts had forecast. Revenues of AU$97m came in 3.9% ahead of analyst predictions. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Pro Medicus after the latest results.The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Pro Medicus' earnings potential next year. Fortunately, they also reconfirme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pro-medicus-limited-asx-pme-043702816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PME","PME.AU"],"gpt_icon":0},{"id":"2511468262","title":"Brokers name 3 ASX shares to buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2511468262","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511468262?lang=en_us&edition=fundamental","pubTime":"2025-02-14 11:08","pubTimestamp":1739502487,"startTime":"0","endTime":"0","summary":"It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:. Analysts at Goldman Sachs have retained their buy rating on this wine giant's shares with a slightly trimmed price target of $12.90. According to the note, the broker has reduced its sales and earnings forecasts slightly through to FY 2027 to reflect stronger Penfolds and Americas sales, offset by weaker Premium Brands sales. Outside this, Goldman points out that Treasury Wine's shares are trading on an FY 2026 P/E of just ~15x, which is inexpensive relative to its consumer coverage. And if it is able to demonstrate added comfort to the market on its Penfolds channel sell-through and sustained US luxury portfolio growth, it expects the stock to re-rate positively. The Treasury Wine share price is trading at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/14/brokers-name-3-asx-shares-to-buy-today-14-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7002","LU2237443622.USD","LU2471134523.USD","LU1791807156.HKD","IE00BSNM7G36.USD","BK4533","LU2471134879.HKD","IE0004086264.USD","LU2237443978.SGD","LU2471134952.CNY","IE00B19Z3581.USD","BK7505","LU2237443895.HKD","LU2750360997.AUD","LU2237443382.USD","LU2237443465.HKD","BK7503","BK4516","LU2750360641.GBP","BK4550","IE0004091025.USD","LU2237443549.SGD","LU1668664300.SGD","BK7094","LU0106831901.USD","BK4504","LU2237438978.USD","PME.AU","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU2471134796.USD","BK4588","BK7097","IE0002270589.USD","BK4552","BK4127","TWE.AU","DHG.AU","IE0034235188.USD","BK4585"],"gpt_icon":0},{"id":"2511688496","title":"Leading broker upgrades Pro Medicus shares to buy rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2511688496","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511688496?lang=en_us&edition=fundamental","pubTime":"2025-02-14 04:44","pubTimestamp":1739479463,"startTime":"0","endTime":"0","summary":"Pro Medicus Limited  shares were under pressure on Thursday. After initially charging to a record high, the health imaging technology company's shares ended the session 3% lower at $279.08. This was driven by the release of a very strong half year result, which fell just a fraction short of the market's lofty expectations. Should you buy Pro Medicus shares?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/14/leading-broker-upgrades-pro-medicus-shares-to-buy-rating/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PME.AU","BK7094"],"gpt_icon":0},{"id":"2511047500","title":"Here's Why We Think Pro Medicus (ASX:PME) Might Deserve Your Attention Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2511047500","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511047500?lang=en_us&edition=fundamental","pubTime":"2025-02-14 04:01","pubTimestamp":1739476911,"startTime":"0","endTime":"0","summary":"Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/heres-why-we-think-pro-medicus-asxpme-might-deserve-your-att-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EBIT","BK7094","BK4212","PME","PME.AU"],"gpt_icon":0},{"id":"2511085566","title":"Pro Medicus hypes up ‘unprecedented success’ in US push – but market not so sold","url":"https://stock-news.laohu8.com/highlight/detail?id=2511085566","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511085566?lang=en_us&edition=fundamental","pubTime":"2025-02-13 12:14","pubTimestamp":1739420040,"startTime":"0","endTime":"0","summary":"Pro Medicus  shares dipped by as much as 4% today, despite the medical imaging IT provider dishing up its “biggest half-year results” when it came to key figures like revenue, net profit growth, and retained earnings.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.On top of that, the $28 billion Healthcare company heralded huge wins in U.S. contract pickups, renewals, and upgrades – an “unprecedented success.”Between several deals, Pro Medicus has teed up as much as $365 million in new contracts over the next decade and re-upped $98 million in extensions with U.S. companies; a further $32 million came from an Aussie radiology provider.By 3pm, Pro Medicus had retreated by $12.56 a share, to sell at $275.75. Ten minutes later, it had rebounded somewhat to sell at just 1.4% down.The material provided in this article is for information only and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/pro-medicus-hypes-up-unprecedented-success-in-us-push-but-market-not-so-sold-2025-02-13/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2511105569","title":"ASX Market Update: Index touches new record as Chemist Warehouse debuts | Feb 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2511105569","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511105569?lang=en_us&edition=fundamental","pubTime":"2025-02-13 11:18","pubTimestamp":1739416680,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.3% at 8,560 points after touching a new all-time high of 8,575 points in intra-day trade.The positive investor sentiment followed the spectacular launch of Chemist Warehouse on the boards through its $34 billion merger with Sigma Healthcare.Materials has been the strongest performer, up 1.2%, followed by Discretionary, up 0.9%, and Telecommunication, up 0.3%. Utilities has been the worst sector, down 1.75%, followed by Energy, -0.75%, and Staples, -0.55%.Austalhas been down 1.8% after inking a deal worth between $265 and $275 million, for the creation of a 130-metre combined cycle, hydrogen-ready vehicle passenger ferry. Austal has been $3.81.Pro Medicus  has been down 4.6% as investors take profits after the company hit a record high following the release of its half-yearly. Pro Medicus has been $274.85.Kalgoorlie Gold Mining  has been up 16.9% after getting things underway to drill at its Lighthorse gold discovery at Pinjin next month.The material provided in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-touches-new-record-as-chemist-warehouse-debuts-feb-13-2025-2025-02-13/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["PME.AU","BK7104","BK7094","KAL.AU","ASB.AU","BK7115"],"gpt_icon":0},{"id":"2511550614","title":"\"I’ll be buying\" – Why Jun Bei Liu sees more upside in Pro Medicus","url":"https://stock-news.laohu8.com/highlight/detail?id=2511550614","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511550614?lang=en_us&edition=fundamental","pubTime":"2025-02-13 10:13","pubTimestamp":1739412784,"startTime":"0","endTime":"0","summary":"Despite its sky-high valuation, Jun Bei Liu, co-founder and lead portfolio manager at the newly launched active manager TenCap, remains one of Pro Medicus'  earliest and most vocal champions.She first bought PME five years ago at a bargain price of $25, and the stock has since 10x’d. The big question now: how much higher can it climb?While today’s HY25 results came in line with expectations, Jun Bei remains bullish on the company’s long-term potential, citing its impeccable execution, expanding margins, and growing dominance in the vast U.S. hospital network.STAY TUNED: While Jun Bei Liu shares her take on the results, Livewire Managing EditorChris Conwaywill be speaking with PME CEO Dr. Sam Hupert today. The full video interview will be published on our website—follow him to get notified as soon as it’s live!In particular, I’d like to point out that Morningstar thinks PME has a narrow moat or a limited ability to defend its business from competitors offering a similar product.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/i-ll-be-buying-why-jun-bei-liu-sees-more-upside-in-pro-medicus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/i-ll-be-buying-why-jun-bei-liu-sees-more-upside-in-pro-medicus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2511062557","title":"Pro Medicus logs 42.7% increase in net profit as major contracts drive growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2511062557","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511062557?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:54","pubTimestamp":1739408097,"startTime":"0","endTime":"0","summary":"Health imaging company Pro Medicus  has announced a net profit of $51.7 million for the six months to the end of December 2024, representing a 42.7% increase on the previous corresponding period.Revenue from ordinary activities was up 31.1% to $97.2m, driven largely by increased sales from North America, where regional revenue rose 34.6% to $86.4m.The company’s cash and other financial assets in December increased 17.7% to $182.3m and it remains debt-free.Pro Medicus won key contracts with Trinity Health, Lurie Children’s Hospital and Duly Health and Care during the period, worth a combined minimum amount of $365m spread over individual deals spanning up to 10 years.The Trinity Health contract alone is valued at $330m and represents the largest win in the company’s history.Additional modules were added to existing contracts at Duke Health  and NYU Langone .Dr Hupert said the Pro Medicus contract pipeline remained strong across client classes as it continues to address all market segmen","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/ProMedicus-ASX-PME-December-2024-half-yearly-result.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/ProMedicus-ASX-PME-December-2024-half-yearly-result.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/pro-medicus-increase-net-profit-major-contracts-drive-growth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7094","PME.AU"],"gpt_icon":0},{"id":"2511955888","title":"Pro Medicus share price storms higher on record-breaking results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511955888","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511955888?lang=en_us&edition=fundamental","pubTime":"2025-02-13 07:17","pubTimestamp":1739402262,"startTime":"0","endTime":"0","summary":"The Pro Medicus Limited  share price is rising again on Thursday morning. In early trade, the health imaging technology company's shares are up 4% to an all-time high of $298.98. This follows the release of the company's record half year results. Pro Medicus share price higher on record results  Total revenue up 32.15% to a record of $100.79 million Revenue from ordinary activities up 31.1% to $97.2 million Underlying EBIT margin increased from 66% to 72% Underlying profit before tax up 42.9% to $69.9 million Net profit up 42.7% to a record of $51.7 million Earnings per share up 42.7% to 49.53 cents Fully franked interim dividend up 38.9% to 25 cents per share Cash and other financial assets of $182.3 million with no debt  What happened in the first half?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/13/pro-medicus-share-price-storms-higher-on-record-breaking-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PME.AU","BK7094","IDN","BK4157","XKO.AU","BK4023","XAO.AU","XJO.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PME.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-27","symbol":"PME.AU","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-28","name":"PRO MEDICUS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-02-28","currency":"AUD","dateTimestamp":1740574800000,"payDate":"2025-03-21"},{"date":"2025-02-11","symbol":"PME.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739228400000,"name":null,"time":"","dateTimestamp":1739192400000,"actualEps":null},{"date":"2024-09-04","symbol":"PME.AU","amount":0.22,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-05","defaultRemindTime":1725408000000,"name":"PRO MEDICUS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-26","payableDate":"2024-09-05","currency":"AUD","dateTimestamp":1725372000000,"payDate":"2024-09-26"},{"date":"2024-08-14","symbol":"PME.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723593600000,"name":null,"time":"","dateTimestamp":1723557600000,"actualEps":null},{"date":"2024-02-29","symbol":"PME.AU","amount":0.18,"announcedDate":null,"type":"dividend","market":"AU","newRecordDate":"2024-03-01","defaultRemindTime":1709161200000,"name":"Pro Medicus Ltd","recordDate":"2024-03-22","payableDate":"2024-03-01","currency":"AUD","dateTimestamp":1709125200000,"payDate":"2024-03-22"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PME.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-02","value":0.06,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-03-19","value":0.07,"currency":"AUD"},{"executeDate":"2021-09-09","recordDate":"2021-09-10","paymentDate":"2021-10-01","value":0.08,"currency":"AUD"},{"executeDate":"2022-03-03","recordDate":"2022-03-04","paymentDate":"2022-03-25","value":0.1,"currency":"AUD"},{"executeDate":"2022-09-08","recordDate":"2022-09-09","paymentDate":"2022-09-30","value":0.12,"currency":"AUD"}]}}